Early (<10 mm) HER2-Positive Invasive Breast Carcinomas are Associated with Extensive Diffuse High-Grade DCIS: Implications for Preoperative Mapping, Extent of Surgical Intervention, and Disease-Free Survival
- 326 Downloads
The few publications on <10-mm invasive breast carcinomas have reported worse outcomes for women with human epidermal growth factor receptor 2 (HER2)-positive cancer compared with HER2-negative cases and indicated that the high risk of recurrence in HER2-positive cases is related to the high grade, hormone receptor negativity, and high proliferation index of the invasive tumor component.
We studied the subgross morphology of such tumors in a consecutive series of 203 cases documented in large-format histology slides and worked up with detailed radiological–pathological correlation.
The invasive component was associated with a diffuse in situ component in 78 % of the HER2-positive and 26 % of HER2-negative tumors <10 mm in size (odds ratio [OR], 11.3936; P < .0001). The in situ component was of high grade in 75 % of HER2-positive and 9 % of HER2-negative cases (OR, 29.6000; P < .0001). Significant associations were also found between the HER2 positivity of the invasive component and diffuse combined lesion distribution (P > .0001), invasive tumor grade 3 (P = .0004), presence of vascular invasion (P = .0026), extensive disease (P = .0170), “not special” (ductal) histological tumor type (P = .0302), estrogen receptor negativity (OR, 7.8846; P < .0001), and high Ki67 proliferation index (OR, 5.0000; P = .0007). The HER2-positive tumors tended to be multifocal (OR, 2.000) and lymph node-positive (OR, 3.0147), but the tendency was not statistically significant.
The vast majority of <10-mm HER2-positive breast carcinomas exhibited a high-grade, diffuse, and extensive in situ component, which may explain the high risk of recurrence among these tumors.
KeywordsInvasive Breast Carcinoma Epithelial Growth Factor Receptor Invasive Component High Ki67 Proliferation Index Sick Lobe
The author is thankful to his excellent colleagues: Drs. Nadja Lindhe, Mats Ingvarsson, and Prof. Laszlo Tabár, radiologists; Drs. Anders Cohen, Gunilla Christensson, and Maria Annerbo, breast surgeons; Drs. Maria Gere, Gyula Pekár, Syster Hofmeyer, breast pathologists; and all the other members of the Multidisciplinary Breast Team at Falun Central Hospital.
- 3.Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. American Society of Clinical Oncology; College of American Pathologists. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013:31:3997–4013.PubMedCrossRefGoogle Scholar
- 10.Tabar L, Chen THH, Yen AMF, Tot T, Tung TH, Chen LS, et al. Mammographic tumor features can predict long-term outcomes reliably in women with 1–14-mm invasive breast carcinoma. Suggestions for the reconsideration of current therapeutic practice and the TNM classification system. Cancer. 2004;101:1745–59.PubMedCrossRefGoogle Scholar
- 11.Tot T, Pekár G, Hofmeyer S, Gere M, Tarján M, Hellberg D, Lindquist D. Molecular phenotypes of unifocal, multifocal, and diffuse invasive breast carcinomas. Pathol Res Int. 2011, Article ID 480960.Google Scholar
- 13.Tot T, Tabár L, Dean PB. Practical breast pathology. New York: Thieme, 2002. pp. 115–23.Google Scholar
- 15.Lindquist D, Tot T. Disease extent ≥4 cm is a prognostic marker of local recurrence in T1–2 breast cancer. Pathol Res Int. 2011, Article ID 860584.Google Scholar
- 16.AJCC cancer staging handbook, 7th ed. New York: Springer; 2010.Google Scholar
- 17.Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ, editors. WHO classification of tumours of the breast. Lyon: International Agency for Research on Cancer (IARC); 2012.Google Scholar
- 19.Nitta H, Kelly BD, Padilla M, Wick N, Brunhoeber P, Bai I, et al. A gene-protein assay for human epidermal growth factor receptor 2 (HER2): brightfield tricolor visualization of HER2 protein, the HER2 gene, and chromosome 17 centromere (CEN17) in formalin-fixed, paraffin-embedded breast cancer tissue sections. Diagn Pathol. 2012;7:60.PubMedCentralPubMedCrossRefGoogle Scholar
- 24.Bijker N, Peterse JL, Duchateau L, Robanus-Maandag EC, Bosch CA, Duval C, et al. Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ. Br J Cancer. 2001;84:539–44.PubMedCentralPubMedCrossRefGoogle Scholar